Cargando…
Loading, please waitCargando…
Loading, please waitCondition × Stem Cells
A physician-led look at where mesenchymal stem cell (MSC) therapy stands for meniscus tears: what the published clinical evidence actually shows, who qualifies and who does not, and how care is delivered under COFEPRIS regulation at our clinic in Cancún, México. No prices are published online — every case is reviewed in a free medical evaluation, then quoted in writing.
TL;DR
Mesenchymal stem cell (MSC) therapy is an investigational, physician-led option for meniscus tears that may reduce pain, support biological healing, and — in some patients — increase meniscal volume on MRI. Best-quality human evidence comes from a small randomized trial after partial medial meniscectomy and a first-in-human study in avascular tears; it is promising, not proven. At Regeneris Therapy in Cancún, México, every case starts with a free medical evaluation; only after that do you receive a personalized written quote.
The condition
The menisci are two crescent-shaped fibrocartilage pads that sit between the femur and tibia inside the knee. They distribute load, absorb shock, lubricate joint surfaces, and help stabilize the joint during walking, squatting, pivoting, and sport. A meniscus tear is a structural disruption of that tissue — common in athletes from twisting injuries, and increasingly common in older adults as the tissue thins and degenerates with age.
What the research shows
Peer-reviewed clinical evidence for MSC therapy in meniscus pathology is encouraging but still limited. Most of the published literature is preclinical (cell-culture and animal models); the human studies that exist are small in number and modest in size, and reviewers — including the field's own systematic reviewers — are explicit that larger, longer randomized controlled trials are needed before MSCs can be considered an established treatment for this condition. The notes below summarize the strongest sources we cite and what each does and does not show. None of it guarantees an individual outcome.
A multicenter, randomized, double-blind, controlled trial assigned 55 adults to a single intra-articular injection of allogeneic adult human MSCs (at one of two doses) or sodium hyaluronate control 7-10 days after partial medial meniscectomy. At one-year follow-up, no abnormal tissue formation was reported, a subset of treated knees showed at least a 15% increase in meniscal volume on MRI (24% of one MSC group and 6% of the other vs none in the control), and treated patients reported a greater reduction in pain. The authors framed the results as supportive of safety and a possible regenerative signal — not as a definitive efficacy claim.
A prospective, open-label first-in-human safety study took five patients with an avascular meniscal tear from in-vitro optimization through a preclinical sheep model and into surgical implantation of autologous, undifferentiated bone-marrow MSCs seeded on a collagen scaffold at the time of repair, with 24-month follow-up. The series was small but reported acceptable safety and feasibility, with three of five patients clinically asymptomatic at two years — supporting further clinical development for tears in the poorly vascularized 'white' zone.
A systematic review of preclinical and clinical evidence found that across the published studies, stem cell-based approaches showed generally favorable laboratory, clinical, and radiologic outcomes for meniscal tears, with bone-marrow-derived MSCs delivered by intra-articular injection the most commonly studied combination. The authors explicitly conclude that it is not yet possible to identify a single best cell source or delivery method, and that larger randomized controlled trials with longer follow-up are needed before firm recommendations can be made — a stance that should anchor any honest patient conversation.
A focused narrative review summarizing how MSCs may contribute to meniscal repair: locally applied MSCs produced differentiated meniscus-like tissue in experimental tears, suggesting these cells can augment biological healing in critical-size injuries where standard repair shows a meaningful failure rate. The mechanism is consistent with how MSCs work elsewhere — through paracrine secretion of growth factors and exosomes that recruit local progenitor cells and modulate inflammation, not by replacing the meniscus directly.
Mechanistic context that frames the meniscus literature. The field's founding figure reframed MSCs as 'medicinal signaling cells,' arguing their therapeutic benefit comes chiefly from secreted, paracrine factors — exosomes, growth factors, cytokines — rather than from engraftment and tissue replacement. This is the underlying mechanism most often invoked to explain why an MSC injection can reduce inflammation and support healing in a knee joint without literally rebuilding the meniscus from scratch.
Read together, the literature supports a careful, conservative position: MSC therapy is biologically rational for meniscus tears and shows a clinical signal in small randomized and first-in-human studies, but it remains investigational. Whether it is right for your specific tear is a medical question — confirmed only in evaluation, never assumed from a search query.
Candidacy
MSC therapy for meniscus tears is not a first-line treatment, and it is not a fit for every patient. The lists below describe the general clinical factors that point toward or away from regenerative care for this condition at our clinic in Cancún, México. None of these supersede a physician evaluation — they orient you before one.
Regulation & location
Regeneris Therapy operates as a physician-led regenerative-medicine clinic in Cancún, Quintana Roo, México, under COFEPRIS — México's federal health authority, the regulatory equivalent of the U.S. FDA. That framework defines who may prescribe and deliver stem cell therapy, where cells may be processed, and what advertising claims a clinic may publish.
Our clinic operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053, the federal records that authorize medical operations and regulate any advertising of regenerative therapies in México.
Cells used in our protocols are expanded under sterile, COFEPRIS-certified laboratory conditions with donor screening and quality-control testing — a baseline patients and families should expect from any serious clinic.
Every protocol is prescribed and supervised by a licensed Mexican physician at our clinic in Cancún, México. Care is not delegated to non-physician staff, and decisions are documented in your written plan.
Patients traveling to Cancún, México from the United States, Canada, or elsewhere often combine evaluation, treatment, and rest on a single short itinerary; our team helps coordinate the medical side from your first message.
How we work
Our model is intentionally medical, not transactional. We do not publish prices online for stem cell therapy, and we do not sell a fixed package. Every meniscus case starts with a structured physician evaluation and ends with a written plan and a personalized quote — so you can make an informed decision before committing.
Share your goals, recent MRI, prior imaging, surgical history, medications, and any conditions. A Regeneris physician reviews your case — by message or video first if you are traveling from outside Cancún — and answers honestly whether MSC therapy is worth considering for your tear.
We confirm tear type, location (red vs white zone), severity, and the state of the surrounding cartilage and ligaments. If imaging is incomplete, we tell you what is needed before any decision is made.
If MSC therapy is appropriate, you receive a written plan describing cell source, route of administration, number of sessions, post-procedure rehabilitation, and the personalized quote — clearly stated, no surprises. You take the document home and decide on your own time.
If you proceed, treatment is delivered at our clinic in Cancún, México under physician supervision, with structured follow-up. We reassess outcomes honestly — including the option to refer you onward if surgery becomes the better answer.
This is the same workflow whether you are a Cancún resident, a Mexican patient from another state, or an international patient flying in: free evaluation first, written quote only after we understand your case.
Honest expectations
We treat this section as the most important on the page. Marketing language in regenerative medicine has historically run ahead of the evidence; we are deliberately conservative because honesty is the only defensible position in a YMYL medical field.
FAQ
The questions patients ask us most when considering MSC therapy for a meniscus tear at our clinic in Cancún, México.
The honest answer is: sometimes, partially, and not for every tear. Published clinical evidence — including the Vangsness 2014 randomized trial after partial meniscectomy and the Whitehouse 2017 first-in-human study in avascular tears — supports a biological signal: a subset of patients show increased meniscal volume on MRI, reduced pain, and good early safety. But MSC therapy for meniscus tears is still classified as investigational, and outcomes vary by tear location, severity, and patient. A Regeneris physician will tell you honestly, after evaluation, whether your specific tear is reasonable to treat this way.
No — and any clinic that says otherwise is overpromising. Some tears clearly need surgery (for example, a displaced bucket-handle tear locking the knee, or an end-stage joint that needs definitive management). In other cases — especially degenerative tears in patients with persistent symptoms despite physical therapy, or post-surgical patients looking for adjunctive support — MSC therapy may be a reasonable adjunct or alternative to consider. The decision is medical, made after imaging and an evaluation at our clinic in Cancún, México.
For meniscus pathology, the most studied route in the published literature is intra-articular injection — placing the cell preparation directly into the knee joint, under sterile conditions and physician supervision, either alone or in conjunction with another procedure such as repair. Some surgical protocols (as in the Whitehouse 2017 study) deliver MSCs on a scaffold at the time of repair. Your written plan describes exactly which route applies to you and why, with no hidden steps.
Onset is gradual, not immediate. Anti-inflammatory effects can build over several weeks; structural responses, when they occur, are typically measured across one to several months. We schedule structured follow-up to assess symptoms and function honestly over that window — including the option to refer you onward if the response is not what you and your physician hoped for.
In published studies of MSC therapy for meniscus tears, including the Vangsness 2014 trial and the Whitehouse 2017 first-in-human series, no abnormal tissue formation was reported and the early safety profile was acceptable in small samples. Common risks of any intra-articular injection — temporary soreness, swelling, low risk of infection — are reviewed with you in your evaluation. Patients with active malignancy, active infection, pregnancy, or uncontrolled immunosuppression are generally deferred without specialist coordination.
Regeneris does not publish prices online for stem cell therapy. Our model is intentional: free medical evaluation first, then a written plan and a personalized quote that reflect your specific tear, imaging, and goals. We chose this approach because medicine is not a catalog purchase — a number on a homepage cannot fairly represent the decision you are making about your knee. Your full quote is delivered in writing after evaluation, with no obligation to proceed.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
Continue exploring
The full pillar on mesenchymal stem cell therapy at Regeneris: cell sources, mechanism, protocols, and how to start.
ContinueHow COFEPRIS regulates regenerative medicine in México, what donor screening looks like, and how to evaluate any clinic claim.
ContinueTravel, evaluation, and follow-up logistics for cross-border patients coming to our clinic in Cancún, México.
ContinueA 2026 comparison of cost, regulation, available cell types, and travel logistics for cross-border regenerative care.
ContinueSend your goals and imaging — we'll route your message to a physician for a free medical evaluation.
ContinueThis page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for meniscus tears is investigational; outcomes vary by patient, tear type, and protocol, and no individual response is guaranteed. The decision to pursue MSC therapy is a medical decision that requires an individualized evaluation with a licensed physician; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your goals, recent MRI, and any prior surgery notes. A Regeneris physician will review your case from Cancún, México and tell you — honestly — whether MSC therapy is worth considering, what protocol may fit, and what the personalized written quote would look like after your free medical evaluation.